2025
Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program.
Forman R, Kwaramba T, Shamilov R, Goldberg S, Lee A, Srikumar T. Implementation of a novel interdisciplinary pharmacology curriculum in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2025, 43: 9028-9028. DOI: 10.1200/jco.2025.43.16_suppl.9028.Peer-Reviewed Original ResearchMechanism of actionCase-basedFellowship programsCancer-directed therapyDrug mechanism of actionTreatment decision makingDosing considerationsPharmacology curriculumToxicity managementTreatment optionsPatient counselingInterdisciplinary patient careLearning science principlesCancer therapeuticsPre-post designCase-based formatPost-lecture surveysThematic qualitative analysisActive learningDrug mechanismsCase-based approachDisease typePost-survey respondentsCase-based curriculumCareer transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis.
Xing J, Wang Q, Tang Y, Lu C, Chen F, Roy A, Deng L, Neupane K, Ardeshir Larijani F, Bekaii-Saab T, Aggarwal C, Lee A, Owonikoko T, Chavez Mac Gregor M, Bakouny Z, Gandhi S, Dizman N, Choueiri T, Perimbeti S, Jiang C. Career transitions and practice patterns among international medical graduates in oncology workforce: A US nationwide analysis. Journal Of Clinical Oncology 2025, 43: 9009-9009. DOI: 10.1200/jco.2025.43.16_suppl.9009.Peer-Reviewed Original ResearchInternational medical graduatesRural-Urban Continuum CodesCancer care deliveryOncology workforceMedical graduatesCare deliveryMedical oncologistsUS graduatesNCI-designated cancer centersDesignated cancer centersCross-sectional studyNon-metropolitan areasContinuum CodesWorkforce disparitiesUnderserved regionsSystemic barriersCareer stagesChi-square testPrimary specialtyPracticing medical oncologistsNCI centersStratified analysisAcademic affiliationPractice patternsPrimary outcomeBoard certification practices of US hematologists and oncologists.
Wesevich A, Schmitt L, Wesevich M, Lee A. Board certification practices of US hematologists and oncologists. Journal Of Clinical Oncology 2025, 43: 9034-9034. DOI: 10.1200/jco.2025.43.16_suppl.9034.Peer-Reviewed Original ResearchCenters for Medicare & Medicaid ServicesAmerican Board of Internal MedicineMaintenance of certificationTeaching hospitalCareer pathwaysRural-Urban Commuting Area codesCertification practicesFemale genderMedical school graduatesSchool graduatesNon-teaching hospitalsMedicare Part BPhysician characteristicsArea codeMedicaid ServicesTrained physiciansNon-metropolitanInternal medicineOpen PaymentsCredentialing practicesMedical schoolsOncology boardUnited StatesFellowship programsMedical oncologistsAmerican Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary
Siegal D, Tseng E, Schünemann H, Angchaisuksiri P, Cuker A, Dane K, DeSancho M, Diuguid D, Griffin D, Klok F, Lee A, Neumann I, Pai A, Righini M, Sanfilippo K, Terrell D, Akl E, Al Jabiri R, Al Jabiri Y, Barbara A, Bognanni A, Akl I, Boulos M, Brignardello-Petersen R, Chan M, Charide R, Colunga-Lozano L, Dearness K, Darzi A, Hussein H, Karam S, Kolb P, Mansour R, Morgano G, Morsi R, Muti-Schünemann G, Nadim M, Noori A, Philip B, Piggott T, Qiu Y, Benitez Y, Schünemann F, Stevens A, Solo K, Wiercioch W, Mustafa R, Nieuwlaat R. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Advances 2025, 9: 1247-1260. PMID: 39437797, PMCID: PMC11950770, DOI: 10.1182/bloodadvances.2024014219.Peer-Reviewed Original ResearchConceptsCOVID-19-related critical illnessConditional recommendationAcute illnessHealth care professionalsAmerican Society of HematologyProphylactic-intensity anticoagulationCritical illnessEvidence-based recommendationsVenous thromboembolismRandomized controlled trialsCare professionalsPatient representativesRisk of venous thromboembolismGuideline developmentRecommendations AssessmentTherapeutic-intensity anticoagulationExecutive summaryLiving guidelinesMultidisciplinary panelIncreased risk of venous thromboembolismSystematic reviewAssessed certaintyCOVID-19-relatedControlled trialsMcMaster UniversityInitial management of patients with acquired aplastic anemia in the United States: results from a large national claims database
Stempel J, Wang R, Lee A, Zeidan A, Ma X, Podoltsev N. Initial management of patients with acquired aplastic anemia in the United States: results from a large national claims database. Annals Of Hematology 2025, 104: 2507-2515. PMID: 40102305, PMCID: PMC12052795, DOI: 10.1007/s00277-025-06307-z.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantationAcquired aplastic anemiaCalcineurin inhibitorsParoxysmal nocturnal hemoglobinuriaTransfusion-dependentTriple therapyAA patientsAplastic anemiaAllogeneic hematopoietic stem cell transplantationTreated with calcineurin inhibitorsTreated with antithymocyte globulinFlow cytometryInitial management of patientsSevere AA patientsStem cell transplantationBone marrow failureImmune-mediated disordersTreatment initiation delayRetrospective cohort studyManagement of patientsDiagnosis to treatmentNational claims databaseAntithymocyte globulinSibling donorMarrow failureIntercontinental variations in the presentation and management of venous thromboembolism
Chaar C, Chan S, Lee A, Bikdeli B, Tiberio G, Chopard R, Weinberg I, Yamashita Y, Nikandish R, Monreal M. Intercontinental variations in the presentation and management of venous thromboembolism. JVS-Vascular Insights 2025, 3: 100201. DOI: 10.1016/j.jvsvi.2025.100201.Peer-Reviewed Original ResearchManagement of venous thromboembolismVenous thromboembolismPulmonary embolismLow-risk pulmonary embolismTreatment modalities of patientsOpen pulmonary embolectomyVenous thromboembolism presentationHigh-risk PEIntermediate-risk PELow-molecular-weight heparinLower body mass indexVitamin K antagonistsSystemic thrombolytic therapyProportion of patientsVenous thromboembolism patientsBody mass indexCoronary artery diseaseTreatment of PEPulmonary embolectomyK antagonistsOral anticoagulantsProximal DVTActive cancerOutpatient anticoagulationEndovascular treatment
2024
In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor
Restrepo-Espinosa V, Lee A, Prozora S, Patel P, Nassiri N. In-human clinical experience with direct stick embolization of low-flow vascular malformations using a mammalian target of rapamycin inhibitor. Journal Of Vascular Surgery Venous And Lymphatic Disorders 2024, 13: 101997. PMID: 39515753, PMCID: PMC12014304, DOI: 10.1016/j.jvsv.2024.101997.Peer-Reviewed Original ResearchLow-flow vascular malformationsMTOR inhibitorsClinical successVascular malformationsSide effectsLocalized intravascular coagulopathyOral aphthous ulcersKlippel-Trenaunay syndromeLymphatic malformationsVenous malformationsRe-interventionDelayed complicationsNon-syndromicTechnical successAphthous ulcersIntravascular coagulopathyD-dimerEndovascular treatmentSystemic exposureAdjunctive therapySystemic toxicityFrequent bloodMalformationsSelf-limitingMTOR inhibitionUse of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database
Stempel J, Wang R, Lee A, Ma X, Podoltsev N. Use of Calcineurin Inhibitor (CNI) and Eltrombopag (EPAG) Among Patients with Acquired Aplastic Anemia (AA) in the United States: Results from a Large National Database. Blood 2024, 144: 2319. DOI: 10.1182/blood-2024-202185.Peer-Reviewed Original ResearchHorse anti-thymocyte globulinLow transfusion burdenAcquired aplastic anemiaCalcineurin inhibitor levelsCalcineurin inhibitorsSevere AARed blood cellsEltrombopag therapyTransfusion burdenMedian proportion of daysTransfusion of red blood cellsCalcineurin inhibitor agentsMedian starting doseAnti-thymocyte globulinDiagnosis to initiationTransplant-ineligible patientsBone marrow failureRare autoimmune disorderReduce transfusion requirementsBaseline red blood cellRetrospective cohort studyStudent's t-testProportion of daysBlue Cross Blue ShieldElixhauser comorbidity scoreCost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria
Ito S, Chetlapalli K, Wang D, Potnis K, Richmond R, Krumholz H, Lee A, Cuker A, Goshua G. Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria. Blood 2024, 145: 127-140. PMID: 39374533, PMCID: PMC11738035, DOI: 10.1182/blood.2024025176.Peer-Reviewed Original ResearchStandard-of-careParoxysmal nocturnal hemoglobinuriaIncremental net monetary benefitNocturnal hemoglobinuriaComplement-mediated hemolytic anemiaTreating paroxysmal nocturnal hemoglobinuriaComplement C5 inhibitor eculizumabPhase 3 studyQuality-adjusted life expectancyRare blood disorderComprehensive cost-effectiveness analysisProbabilistic sensitivity analysesCost-saving thresholdsC5 inhibitor eculizumabNet monetary benefitPersistent anemiaIptacopanExtravascular hemolysisIntravenous infusionMonotherapyHemolytic anemiaAnemia resolutionC5 inhibitionFDA approvalPrimary outcomeGuide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice
Dizman N, Bakouny Z, Haykal T, Riano I, Desai A, Butt A, Basu A, Zhao D, Saad E, Saliby R, Gosain R, Gosain R, Ardeshir F, Deng L, Matt-Amaral L, Arnaoutakis K, Bekaii-Saab T, Manochakian R, Marshall A, Forde P, Murphy M, Subbiah V, Chavez-MacGregor M, Owonikoko T, Lopes G, Aggarwal C, Lee A, Choueiri T. Guide to Understanding and Supporting International Medical Graduates in Hematology/Oncology by the ASCO International Medical Graduates Community of Practice. JCO Oncology Practice 2024, 21: 292-299. PMID: 39374449, DOI: 10.1200/op-24-00565.Peer-Reviewed Original ResearchInternational medical graduatesOncology workforceMedical graduatesContribution of international medical graduatesDiverse population of patientsOncology professionalsHematology/oncology fellowsUnited StatesFellowship trainingDiverse populationsMedical oncologyGreater awarenessPopulation of patientsWorkforceOncologyPracticing oncologistsSignificant hardshipASCOEarly career positionsUnique challengesCareer positionsHigh-qualityCommunities of practiceAwarenessCommunityEvaluating the impact of a year-long external mentorship pilot program in classical hematology
Qureshy Z, Nair P, Vesely S, King A, Lee A, Connell N, von Drygalski A, Wong-Sefidan I, Murphy M, Mistry R, Zon R, Reid E, Fritz J, Park S. Evaluating the impact of a year-long external mentorship pilot program in classical hematology. Blood Advances 2024, 8: 4833-4844. PMID: 39087874, PMCID: PMC11416643, DOI: 10.1182/bloodadvances.2024013218.Peer-Reviewed Original ResearchConceptsMentorship programMixed-methods sequential explanatory designScholarly projectsPerceived positive impactSequential explanatory designFocus groupsHematology/oncology fellowsMentee focus groupMedical education institutionsPilot programMentorship opportunitiesMentor respondentsEffective mentorshipMedical oncologyExplanatory designMentor surveysFaculty mentorsMentee perceptionsMentorshipProfessional identityMenteesPhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityFactor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 148: 220-225. PMID: 39004080, PMCID: PMC12106121, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic toolLongitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program. EMJ Oncology 2024, 1: 37-39. DOI: 10.33590/oncolamj/zgwb5064.Peer-Reviewed Original ResearchTrainees’ perspectives on sickle cell education: a qualitative needs assessment
Prince E, Feder K, Calhoun C, Lee A, Carroll C, Restrepo V, Van Doren L. Trainees’ perspectives on sickle cell education: a qualitative needs assessment. BMC Medical Education 2024, 24: 715. PMID: 38956512, PMCID: PMC11220977, DOI: 10.1186/s12909-024-05696-5.Peer-Reviewed Original ResearchConceptsNeeds assessmentPatient care challengesIterative thematic analysisQualitative needs assessmentCost of careComplications of SCDBackgroundSickle cell diseaseCare challengesHealthcare biasesSpecific educationThematic analysisMedical traineesFocus groupsClinical careTrainees' attitudesQualitative interviewsLack of national standardsLongitudinal exposureClinical teachingUnited StatesExpert cliniciansSubspecialty trainingTraineesCareHealthcareLongitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program.
Srikumar T, Stempel J, Goldberg S, Podoltsev N, Braun D, Lee A, Sanft T. Longitudinal curriculum to address wellness and professional development in a hematology/oncology fellowship program. Journal Of Clinical Oncology 2024, 42: 9004-9004. DOI: 10.1200/jco.2024.42.16_suppl.9004.Peer-Reviewed Original ResearchNeeds assessmentLongitudinal curriculumPatient Health Questionnaire 2Score of self-efficacyGeneral Self-Efficacy ScaleFellowship programsBaseline needs assessmentFaculty-led sessionsProfessional boundary settingSelf-Efficacy ScaleLevels of depressionProfessional developmentFirst-year fellowsDidactic sessionsPrevent burnoutChi-square testAcademic yearDebriefing sessionsQuestionnaire 2Baseline assessmentSelf-efficacyProfessional development skillsDepressed moodLeadership skillsBurnoutInternational medical graduates (IMG) representation at international oncology conference meetings.
Roy A, Bakouny Z, Dizman N, Ozay Z, Mohan Lal B, Nawfal R, Eid M, El Hajj Chehade R, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall A, Murphy M, Owonikoko T, Lee A, CHOUEIRI T. International medical graduates (IMG) representation at international oncology conference meetings. Journal Of Clinical Oncology 2024, 42: 9000-9000. DOI: 10.1200/jco.2024.42.16_suppl.9000.Peer-Reviewed Original ResearchInternational medical graduatesAmerican medical graduatesASCO Annual MeetingMedical graduatesFaculty rolesMedical schoolsAmerican Society of Clinical Oncology (ASCOUS institutionsInternational oncology meetingsOncology workforceUnder-recognitionOncology meetingsSelection of presentationsAssess factorsMultivariate analysisPracticing oncologistsUS-basedASCOConference meetingsAcademic rankOriginal researchHighest proportionPodium presentationsAmerican SocietyUnited StatesCost‐effectiveness of sutimlimab in cold agglutinin disease
Ito S, Wang D, Purcell A, Chetlapalli K, Lee A, Cuker A, Goshua G. Cost‐effectiveness of sutimlimab in cold agglutinin disease. American Journal Of Hematology 2024, 99: 1475-1484. PMID: 38733355, DOI: 10.1002/ajh.27358.Peer-Reviewed Original ResearchPrimary cold agglutinin diseaseCold agglutinin diseaseStandard-of-careIncremental cost-effectiveness ratioUS willingness-to-pay thresholdRare autoimmune hemolytic anemiaPhase 3 studyWillingness-to-pay thresholdsAutoimmune hemolytic anemiaTime-limited treatmentHuman monoclonal antibodyCold-reactive antibodiesBinding to red blood cellsFollow-up dataCost-effectiveness ratioComplement-mediated hemolysisDeterministic sensitivity analysisHealth resource utilizationProbabilistic sensitivity analysesTransfusion-dependentClinical remissionTransfusion supportImprove quality of lifeRed blood cellsHemolytic anemiaProviding 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment
Butt A, Christian J, Kress A, Lu B, Hurwitz M, Goldberg S, Podoltsev N, Gilkes L, Lee A. Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment. Journal Of Cancer Education 2024, 39: 325-334. PMID: 38430454, DOI: 10.1007/s13187-024-02414-z.Peer-Reviewed Original ResearchFull-time equivalent supportFull-time equivalentAmerican Council for Graduate Medical EducationCore facultyFellowship programsFellowship educationGraduate Medical EducationImprove job satisfactionCF programPotential unintended consequencesMedical educationSalary supportSurvey respondentsIncreased participationMedical oncologyUnintended consequencesSubspecialty fellowshipsIncreased senseSense of commitmentJob satisfactionFellowshipEducationFaculty involvementEndovascular treatment of renal vein thrombosis in a young patient with lung transplant
Rodriguez P, Brahmandam A, Turner J, Lee A, Chaar C. Endovascular treatment of renal vein thrombosis in a young patient with lung transplant. Journal Of Vascular Surgery Cases And Innovative Techniques 2024, 10: 101437. PMID: 38464891, PMCID: PMC10924198, DOI: 10.1016/j.jvscit.2024.101437.Peer-Reviewed Original ResearchRenal vein thrombosisInferior vena cavaRenal functionVein thrombosisTreatment of renal vein thrombosisLeft renal vein thrombosisPatient's renal functionSuprarenal IVC filterDouble-lung transplantationMagnetic resonance venogramPercutaneous pharmacomechanical thrombectomyAcute kidney injuryFlank painRare entityTherapeutic anticoagulationIVC filtersPharmacomechanical thrombectomyVena cavaMedical therapyEndovascular treatmentYounger patientsInitial managementKidney injuryThrombosisThrombectomy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply